logo
How safe are the chemicals in sunscreen?

How safe are the chemicals in sunscreen?

Business Times4 days ago
LAST week, the Australian Therapeutic Goods Administration (TGA) released its safety review of seven active ingredients commonly used in sunscreens. It found five were low-risk and appropriate for use in sunscreens at their current concentrations.
However, the TGA recommended tighter restrictions on two ingredients – homosalate and oxybenzone – to reduce how much can be used in a product. This is based on uncertainty about their potential effects on the endocrine system, which creates and releases hormones.
This news, together with recent reports that some products may have inflated their claims of SPF coverage, might make consumers worried about whether their sunscreen products are working – and safe.
But it's not time to abandon sunscreens. In Australia, all sunscreens must pass a strict approval process before going on the market. The TGA tests the safety and efficacy of all ingredients, and this recent review is part of the TGA's continuing commitment to safety.
The greatest threat sunscreen poses to people's health is not using it. Australia has the highest incidence of melanoma and non-melanoma skin cancer worldwide, and approximately 95 per cent of melanoma cases in Australia are linked to ultraviolet (UV) exposure.
Still, it's understandable people want to know what's in their products, and any changes that might affect them. So let's take a closer look at the safety review and what it found.
A NEWSLETTER FOR YOU
Friday, 2 pm Lifestyle
Our picks of the latest dining, travel and leisure options to treat yourself.
Sign Up
Sign Up
What are the active ingredients in sunscreen?
There are two main types of sunscreen: physical and chemical. This is based on the different active ingredients they use.
An active ingredient is a chemical component in a product that has an effect on the body – basically, what makes the product 'work'. In sunscreens, this is the compound that absorbs UV rays from the sun. The other ingredients – for example, those that give the sunscreen its smell or help the skin absorb it – are 'inactive'.
Physical sunscreens typically use minerals, such as titanium dioxide and zinc oxide, that can absorb the sun's rays but also reflect some of them.
Chemical sunscreens use a variety of chemical ingredients to absorb or scatter UV light, both long wave (UVA) or short wave (UVB). The seven active ingredients in this review are in chemical sunscreens.
Why did the TGA do the review?
Australia's current limits for the concentrations of these chemicals in sunscreen are generally consistent with other regulatory agencies, such as the European Union and the US Food and Drug Administration.
However, safety is an evolving subject. The TGA periodically reexamines the safety of all therapeutic goods.
Last year, the TGA revised its method of estimating sunscreen exposure to more closely model how skin is exposed to sunscreens over time. This model considers how much sunscreen someone typically applies, how much skin they cover (whole body versus face and hands, or just face) and how it's absorbed through the skin.
Given this new model – along with changes in the EU and US approaches to sunscreen regulation – the TGA selected seven common sunscreen ingredients to investigate in depth.
Determining what's safe
When evaluating whether chemicals are safe for human use, testing will often consider studies in animals – especially when there is no or limited data on humans. These animal tests are done by the manufacturers, not the TGA.
To take into account any unforeseen sensitivity humans may have to these chemicals, a 'margin of safety' is built in. This is typically a concentration 50 to 100 times lower than the dose at which no negative effect was seen in animals.
The sunscreen review used a margin of safety 100 times lower than this dose as the safety threshold. For most of the seven investigated sunscreen chemicals, the TGA found the margin of safety was above 100. This means they're considered safe and low-risk for long-term use.
However, two ingredients, homosalate and oxybenzone, were found to be below 100. This was based on the highest estimated sunscreen exposure, applied to the body at the maximum permitted concentration: 15 per cent for homosalate, 10 per cent for oxybenzone. At lower concentrations, other uses – such as just the hands and face – could be considered low-risk for both ingredients.
What are the health concerns?
Homosalate and oxybenzone have low acute oral toxicity – meaning you would need to swallow a lot of it to experience toxic effects, nearly half a kilogram of these chemicals – and don't cause irritation to eyes or skin. There is inconclusive evidence about oxybenzone potentially causing cancer in rats and mice – but only at concentrations to which humans will never be exposed via sunscreens.
The key issue is whether the two ingredients affect the endocrine system. While effects have been seen at high concentrations in animal studies, it is not clear whether these translate to humans exposed to sunscreen levels.
No effect has been seen in clinical studies on fertility, hormones, weight gain and, in pregnant women, fetal development. The TGA is being very cautious here, using a very wide margin of safety under worst-case scenarios.
What are the recommendations?
The TGA recommends the allowed concentration of homosalate and oxybenzone be reduced. But exactly how much it will be lowered is complicated, depending on whether the product is intended for adults or children, specifically for the face, or the whole body, and so on.
However, some sunscreens would need to be reformulated or warning labels placed on particular formulations. The exact changes will be decided after public consultation in Australia. Submissions close on Aug 12.
What about benzophenone?
There is also some evidence that benzophenone – a chemical produced when sunscreen containing octocrylene degrades – may cause cancer at high concentrations. This is based on studies in which mice and rats were fed benzophenone well above the concentration in sunscreens.
Octocrylene degrades slowly over time to benzophenone. Heat makes it degrade faster, especially at temperatures above 40 deg C.
The TGA has recommended restricting benzophenone to 0.0383 per cent in sunscreens to ensure it remains safe during the product's shelf life. The Australian Cancer Council advises storing sunscreens below 30 deg C.
The bottom line
The proposed restrictions are very conservative, based on worst-case scenarios. But even in worst-case scenarios, the margin of safety for these ingredients is still below the level at which any negative effect was seen in animals.
The threat of cancer from sun exposure is far more serious than any potential negative effect from sunscreens.
If you do wish to avoid these chemicals before new limits are imposed, several sunscreens are available that provide high levels of protection with little or no homosalate and oxybenzone. For more information, check product labels. THE CONVERSATION
The writer is a senior lecturer in pharmacology at the University of Adelaide
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How safe are the chemicals in sunscreen?
How safe are the chemicals in sunscreen?

Business Times

time4 days ago

  • Business Times

How safe are the chemicals in sunscreen?

LAST week, the Australian Therapeutic Goods Administration (TGA) released its safety review of seven active ingredients commonly used in sunscreens. It found five were low-risk and appropriate for use in sunscreens at their current concentrations. However, the TGA recommended tighter restrictions on two ingredients – homosalate and oxybenzone – to reduce how much can be used in a product. This is based on uncertainty about their potential effects on the endocrine system, which creates and releases hormones. This news, together with recent reports that some products may have inflated their claims of SPF coverage, might make consumers worried about whether their sunscreen products are working – and safe. But it's not time to abandon sunscreens. In Australia, all sunscreens must pass a strict approval process before going on the market. The TGA tests the safety and efficacy of all ingredients, and this recent review is part of the TGA's continuing commitment to safety. The greatest threat sunscreen poses to people's health is not using it. Australia has the highest incidence of melanoma and non-melanoma skin cancer worldwide, and approximately 95 per cent of melanoma cases in Australia are linked to ultraviolet (UV) exposure. Still, it's understandable people want to know what's in their products, and any changes that might affect them. So let's take a closer look at the safety review and what it found. A NEWSLETTER FOR YOU Friday, 2 pm Lifestyle Our picks of the latest dining, travel and leisure options to treat yourself. Sign Up Sign Up What are the active ingredients in sunscreen? There are two main types of sunscreen: physical and chemical. This is based on the different active ingredients they use. An active ingredient is a chemical component in a product that has an effect on the body – basically, what makes the product 'work'. In sunscreens, this is the compound that absorbs UV rays from the sun. The other ingredients – for example, those that give the sunscreen its smell or help the skin absorb it – are 'inactive'. Physical sunscreens typically use minerals, such as titanium dioxide and zinc oxide, that can absorb the sun's rays but also reflect some of them. Chemical sunscreens use a variety of chemical ingredients to absorb or scatter UV light, both long wave (UVA) or short wave (UVB). The seven active ingredients in this review are in chemical sunscreens. Why did the TGA do the review? Australia's current limits for the concentrations of these chemicals in sunscreen are generally consistent with other regulatory agencies, such as the European Union and the US Food and Drug Administration. However, safety is an evolving subject. The TGA periodically reexamines the safety of all therapeutic goods. Last year, the TGA revised its method of estimating sunscreen exposure to more closely model how skin is exposed to sunscreens over time. This model considers how much sunscreen someone typically applies, how much skin they cover (whole body versus face and hands, or just face) and how it's absorbed through the skin. Given this new model – along with changes in the EU and US approaches to sunscreen regulation – the TGA selected seven common sunscreen ingredients to investigate in depth. Determining what's safe When evaluating whether chemicals are safe for human use, testing will often consider studies in animals – especially when there is no or limited data on humans. These animal tests are done by the manufacturers, not the TGA. To take into account any unforeseen sensitivity humans may have to these chemicals, a 'margin of safety' is built in. This is typically a concentration 50 to 100 times lower than the dose at which no negative effect was seen in animals. The sunscreen review used a margin of safety 100 times lower than this dose as the safety threshold. For most of the seven investigated sunscreen chemicals, the TGA found the margin of safety was above 100. This means they're considered safe and low-risk for long-term use. However, two ingredients, homosalate and oxybenzone, were found to be below 100. This was based on the highest estimated sunscreen exposure, applied to the body at the maximum permitted concentration: 15 per cent for homosalate, 10 per cent for oxybenzone. At lower concentrations, other uses – such as just the hands and face – could be considered low-risk for both ingredients. What are the health concerns? Homosalate and oxybenzone have low acute oral toxicity – meaning you would need to swallow a lot of it to experience toxic effects, nearly half a kilogram of these chemicals – and don't cause irritation to eyes or skin. There is inconclusive evidence about oxybenzone potentially causing cancer in rats and mice – but only at concentrations to which humans will never be exposed via sunscreens. The key issue is whether the two ingredients affect the endocrine system. While effects have been seen at high concentrations in animal studies, it is not clear whether these translate to humans exposed to sunscreen levels. No effect has been seen in clinical studies on fertility, hormones, weight gain and, in pregnant women, fetal development. The TGA is being very cautious here, using a very wide margin of safety under worst-case scenarios. What are the recommendations? The TGA recommends the allowed concentration of homosalate and oxybenzone be reduced. But exactly how much it will be lowered is complicated, depending on whether the product is intended for adults or children, specifically for the face, or the whole body, and so on. However, some sunscreens would need to be reformulated or warning labels placed on particular formulations. The exact changes will be decided after public consultation in Australia. Submissions close on Aug 12. What about benzophenone? There is also some evidence that benzophenone – a chemical produced when sunscreen containing octocrylene degrades – may cause cancer at high concentrations. This is based on studies in which mice and rats were fed benzophenone well above the concentration in sunscreens. Octocrylene degrades slowly over time to benzophenone. Heat makes it degrade faster, especially at temperatures above 40 deg C. The TGA has recommended restricting benzophenone to 0.0383 per cent in sunscreens to ensure it remains safe during the product's shelf life. The Australian Cancer Council advises storing sunscreens below 30 deg C. The bottom line The proposed restrictions are very conservative, based on worst-case scenarios. But even in worst-case scenarios, the margin of safety for these ingredients is still below the level at which any negative effect was seen in animals. The threat of cancer from sun exposure is far more serious than any potential negative effect from sunscreens. If you do wish to avoid these chemicals before new limits are imposed, several sunscreens are available that provide high levels of protection with little or no homosalate and oxybenzone. For more information, check product labels. THE CONVERSATION The writer is a senior lecturer in pharmacology at the University of Adelaide

UK agrees deal with Vietnam to remove pharmaceutical trade barriers
UK agrees deal with Vietnam to remove pharmaceutical trade barriers

Business Times

time14-07-2025

  • Business Times

UK agrees deal with Vietnam to remove pharmaceutical trade barriers

[LONDON] Britain said it would strike an agreement with Vietnam to make it easier for pharmaceutical firms to sell UK-made medicines in the South-east Asian nation, under a new trade strategy that emphasises quick, industry-specific deals. Britain launched the new strategy last month, promising a nimbler approach compared to the emphasis it placed on full-fledged free trade agreements following its departure from the European Union. Vietnam will hasten the registration of new medicines and vaccines, while recognising approvals from more regulators, including Britain's Medicines and Healthcare products Regulatory Agency, the British government said in a statement. The deal is expected to be confirmed later on Monday (Jul 14). 'The removal of pharmaceutical barriers with one of our closest trading partners in Asia is a boost for the UK pharmaceutical industry and proof that our Industrial and Trade Strategies are already delivering,' British trade minister Douglas Alexander said. The deal could be worth £250 million (S$432 million) to the British pharmaceutical sector over the next five years, the government added. The UK-Vietnamese Joint Economic and Trade Committee will meet in London on Monday and also discuss financial services and renewable energy. Britain has taken a tougher line on some other sectors, however, with steel imports from Vietnam set to be restricted under a new quota regime. Life sciences, including pharmaceuticals, are a priority sector under Britain's new industrial strategy, which was also launched last month. However, that plan has been delayed by a dispute over drug pricing with the British pharmaceutical sector, which says the government needs to value medicines more fairly and adjust the payments they make back to the health service. REUTERS

China biotech's stunning advance is changing the world's drug pipeline
China biotech's stunning advance is changing the world's drug pipeline

Business Times

time13-07-2025

  • Business Times

China biotech's stunning advance is changing the world's drug pipeline

[HONG KONG] The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way from their copycat days to challenge Western dominance on innovation. The number of novel drugs in China, for cancer, weight-loss and more, entering into development ballooned to over 1,250 last year, far surpassing the European Union and nearly catching up to the US's count of about 1,440, an exclusive Bloomberg News analysis showed. And the drug candidates from the land once notorious for cheap knock-offs and quality issues are increasingly clearing high bars to win recognition from both drug regulators and Western pharmaceutical giants. The findings, gleaned from an analysis of a database maintained by pharma intelligence solutions provider Norstella, show a fundamental shift in medical innovation's centre of gravity. With US President Donald Trump already threatening tariffs on the pharmaceutical sector, China's biotech advances, the scale of which is slowly coming into view, risk becoming another realm of superpower rivalry such as artificial intelligence and electric vehicles. 'The scale itself is not something we have seen before,' said Helen Chen, managing partner at LEK Consulting in Shanghai, who has advised healthcare companies on their China strategy since 2003. 'The products are here, they are attractive and they are fast.' This shift has occurred at an unprecedented pace. When China began to overhaul its drug regulatory system in 2015, the country had just 160 compounds to contribute to the global pipeline of innovative drugs, or less than 6 per cent of the total, behind Japan and the UK. The reforms helped streamline reviews, enforced data quality standards and improved transparency. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up The government's 'Made in China 2025' plan to elevate manufacturing in 10 priority sectors also helped spur a flurry of investments in biotechnology. Altogether, they unleashed a boom led by foreign-educated and -trained scientists and entrepreneurs. 'Not only is it now almost at parity with the US but it has that growth trajectory,' said Daniel Chancellor, vice-president of thought leadership at Norstella. 'It wouldn't be sensationalist to suggest that China will overtake the US in the next few years purely in terms of numbers of drugs that it's bringing through into its pipeline.' Bloomberg News' data analysis focuses on innovative drugs, excluding generic combinations, reformulations and biosimilars. Numbers aside, the more stunning leap is in the quality of Chinese biotech innovation. While there's constant debate in the pharmaceutical industry on whether Chinese firms are capable of producing not just effective but needle-shifting new therapies, there's growing recognition on multiple fronts. The world's strictest regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency, increasingly view Chinese drugs as generally promising enough to justify devoting extra resources to speed up their review, handing them coveted industry designations such as priority review, breakthrough therapy designation or fast track status. The country is now slightly ahead of the EU in earning such expedited reviews as of 2024, the data shows, a remarkable edge over a region that previously produced drugs such as Wegovy. One of the early exemplars of Chinese innovation is a cell therapy that has shown promise to potentially cure a deadly blood cancer. First developed in China by Legend Biotech, it is now marketed by Johnson & Johnson, having won a few expedited review designations along the way, and considered superior to a competing US-originated therapy. Still, the absolute number of China-originated drugs winning these designations trail their US counterparts by a large margin. Risk-aversion remains a factor holding back Chinese pharmaceutical innovation: So far, top companies tend to focus on making better versions of existing therapies or new iterations of older ideas, and few are pioneering novel treatment approaches that have never been tried before, an endeavour that comes with a high risk of failure and is still led by the US, Europe and, to a lesser extent, Japan. Nevertheless, the biggest Chinese breakthroughs are increasingly being snapped up by pharmaceutical giants for record sums, a sign that the perennial competition for the next blockbuster drug is also shifting East. A novel cancer drug from Akeso, which came out more effective than Merck's Keytruda in a Chinese study last year, has been likened to China biotech's DeepSeek moment, spawning a new wave of global interest. The promise of topping Keytruda, the world's top-selling drug, also swelled the valuation of Summit Therapeutics, which in 2022 paid US$500 million upfront for the development and marketing rights in the US and other regions. Other multinational players such as Merck, AstraZeneca and Roche Holding have also scooped up Chinese assets. In May, Pfizer set a new record as it announced a US$1.2 billion upfront deal with 3SBio for a cancer drug similar to Akeso's. These deals are increasing in both value and frequency, according to biopharma deal database DealForma, signalling confidence that China-originated drugs are competitive internationally and can bring in substantial revenue. The volume of potential candidates coming out of China means multinational companies, who have a constant need to add new products to the mix, can 'cast their net wider than ever before', Norstella's Chancellor said. A key advantage that has fuelled the rise of Chinese biotech firms is their ability to conduct research cheaper and faster at every step of the way, from lab experiments and animal testing to human trials. Creating a new drug from scratch is notoriously time-consuming and expensive, and China's massive patient pool and centralised hospital network have become a significant accelerator. An analysis of the time taken for drugs to conduct various testing stages shows that doctors in China can recruit for trials much faster, for early trials for cancer and obesity drugs, they can complete patient enrolment in half the time compared to the US. The difference in costs means Chinese companies can afford to run multiple trials simultaneously to find a winner, or quickly launch new projects once a scientific idea is validated by other groups. Since 2021, China has become the top location for clinical research, initiating the largest number of new trials globally, according to GlobalData. 'They can leapfrog competitors in other countries,' said Andy Liu, head of China at Novotech Health Holdings, which helps companies run clinical trials. To be sure, clinical data in China is just a start. US regulators have made it clear that China-only trial results, no matter how positive, are not sufficient to support drug approvals. Chinese biotechs with the ambition to sell their drugs overseas must prove that their treatment benefits can be replicated in non-Chinese patients, through complex and slower-moving global studies. It may still be a few years before a critical mass of drugs sourced from China wins US and EU approvals, the gold standard for high-quality treatments, and become widely used in the Western world, but many in the industry believe that's inevitable. China's innovators comprise both cutting-edge biotech startups founded by foreign-educated entrepreneurs and old-guard Chinese pharmaceutical companies such as Jiangsu Hengrui Pharmaceuticals, which used to be one of the country's biggest generic drugmakers. The company poured billions of US dollars into shifting to innovative research and development after Beijing's campaign to lower generic drug prices made that sector less profitable. It's now the world's top-ranked pharmaceutical company for the number of new innovative drugs added to the research pipeline in the period of 2020 to 2024. Of the 50 companies that generated the highest number of innovative drug candidates between 2020 and 2024, 20 of them were Chinese, compared to five in the five years before. 'As we move forward, the fact that there's high-quality innovation in China in terms of biotech will no longer be a novelty,' said Ali Pashazadeh, founder and managing director of healthcare advisory firm Treehill Partners in London. 'It will just be an accepted part of the norm.' At a time when China and the US are engaged in renewed geopolitical spats, the growth of China's biotech ecosystem is causing alarm among some American politicians and business leaders. A congressional commission warned that the US risks losing its leadership position in yet another industry critical to national security. 'Biotech is one of the forefronts of the US-China tech rivalry,' said Jack Burnham, research analyst at the think tank Foundation for Defense of Democracies. In addition to economic implications and possible military applications of biotech, China's leverage on innovative therapies may be weaponised in a future conflict, he said, if Americans become dependent on those medicines. The perception of threat has spurred calls for the US government to stymie China's biotech growth, through restrictions such as export controls on scientific equipment and barriers to investment, and boost the domestic biotech sector, including by changing the regulatory environment to emulate countries where clinical trials are run more quickly. Robert F Kennedy, the US Secretary of Health and Human Services, recently pledged to 'Make American Biotech Accelerate'. Despite the risks of the newly combative relationship between the world's two biggest economies, Chinese drugmakers such as Akeso have set their sights on bringing their therapies to developed Western markets. 'The pharma industry is the best industry in the world,' Akeso chief executive officer Michelle Xia said. 'At the end of the day, what we do benefits patients in China, in the US and all around the world.' BLOOMBERG

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store